New Rules on Branch and Representative Offices of Social Organizations: Compliance Implications for Life Sciences Companies Working with Healthcare Industry Associations

On June 30, 2026, China’s Ministry of Civil Affairs issued the Administrative Measures for Branch and Representative Offices of Social Organizations (Ministry of Civil Affairs Order No. 85, the “Measures”), which took effect on August 1, 2026. The Measures establish, for the first time, a unified framework governing the establishment, authorization, financial management, supervision, and legal responsibilities of branch and representative offices of social organizations. Existing offices that do not comply with the Measures must complete corrective action within 12 months.

A key development under the Measures is the increased responsibility placed on social organizations to manage their branch and representative offices. By requiring centralized authorization, financial administration, and supervision, the Measures significantly limit the ability of such offices to operate independently.

Although the Measures apply directly to social organizations, they may also have significant implications for life sciences companies. Healthcare industry associations and their affiliated specialist committees are important partners for life sciences companies conducting academic programs, continuing medical education, research collaborations, and similar activities. The Measures may therefore affect contracting entities, payment arrangements, project approvals, and third-party compliance controls in collaborations with these organizations.

This alert summarizes several key developments under the Measures and outlines practical steps that life sciences companies may consider.

I. Tighter Restrictions on Organizational Structures

Article 6 of the Measures provides: “A social organization may not establish regional branch offices, branch offices based on surname or clan affiliation, branch offices with substantially overlapping memberships, or branch offices with identical or highly similar names or scopes of activities. A social organization may not establish, or establish in disguised form, additional branches or representative offices under an existing branch or representative office.”

Under this provision, organizations operating under names such as the “Jiangsu Branch of the XX Society” or the “South China Working Committee of the XX Research Association” may no longer be permitted. Existing organizations of this kind may need to be restructured during the 12-month transition period.

Some healthcare associations also maintain study groups or working groups under their specialist committees. These structures may face greater scrutiny if they function as secondary-level branches or representative offices. As a result, life sciences companies may have less flexibility to conduct smaller academic programs directly through such study or working groups.

Therefore, when collaborating with an association branch, specialist committee, study group, or similar body, life sciences companies should assess:

• whether the organization is properly established and falls within the association’s authorized internal structure;
• whether it has the authority to undertake the proposed activity;
• whether the relevant contract, payment, and project approval will be centrally administered by the social organization or by a duly authorized branch; and
• whether the organization is improperly conducting activities independently in the name of a study group or working group.
• For third-party conferences, research collaborations, and similar projects, companies should also consider whether the counterparty’s organizational structure has been reviewed and, where necessary, adjusted to comply with the Measures.

II. Stricter Financial Controls

The Measures impose more stringent financial-management requirements on branch and representative offices. In particular, such offices may not:

• transfer, directly or indirectly, revenue generated from activities to the accounts of other organizations or individuals;
• establish separate membership-fee standards, retain membership-fee revenue, or charge duplicative fees;
• enter into donation agreements without authorization, alter the designated use of donated property, or misappropriate or unlawfully retain donated property; or
• open bank accounts.

These requirements reflect the authorities’ continued focus on financial transparency, off-book funds, and unauthorized fees within social organizations.

Therefore, life sciences companies should review the contracting and payment arrangements used for academic sponsorships, conference collaborations, research funding, charitable contributions, and other association-related projects. In particular, companies should verify that payments are made to an authorized organizational account, not to the personal account of an association representative or to an unauthorized third party.

III. Increased Accountability for Social Organizations

Article 26 of the Measures provides that a social organization may be deemed to have failed in its management responsibilities if it does not take effective measures to stop or correct misconduct by a branch or representative office. Relevant misconduct may include:

• conducting activities outside the authorized scope;
• imposing unauthorized fees;
• accepting donations without authorization;
• maintaining unauthorized bank accounts;
• transferring revenue to other organizations or individuals; or
• collaborating with unlawful social organizations.

A social organization that fails to address such conduct may face liability under the Regulations on the Registration and Administration of Social Organizations.

As a result, industry associations and their specialist committees are likely to strengthen internal approval procedures, financial reviews, and project management controls. For life sciences companies, association projects may be subject to additional requirements regarding approvals, contract execution, payments, and implementation. Associations may also revise longstanding collaboration models as part of their compliance efforts.

Therefore, life sciences companies entering into long-term projects should monitor the counterparty’s restructuring and remediation efforts during the transition period and assess whether those changes could affect project implementation.

IV. Recommended Compliance Measures

The Measures provide a 12-month transition period for existing branch and representative offices that do not meet the new requirements. During this period, some industry associations may consolidate, rename, restructure, reauthorize, or dissolve existing offices.

Therefore, life sciences companies should consider the following steps.

1. Review Existing Association Collaborations

Companies should inventory active and planned projects involving industry associations and examine whether:

• the contracting entity, payment recipient, and invoice issuer are consistent;
• the counterparty is properly established and remains validly in existence;
• the counterparty has appropriate authorization from the relevant social organization;
• the proposed activity falls within the counterparty’s authorized scope; and
• the organizational structure complies with the prohibition on secondary-level or disguised branch offices.

2. Enhance Third-Party Due Diligence

Companies should consider incorporating the Measures into their third-party compliance programs. Before entering into a collaboration, they should review:

• the association’s organizational structure;
• the establishment and authorization documents for the relevant branch or committee;
• the association’s status and continuing legal existence;
• any restructuring or remediation undertaken under the Measures;
• any history of unauthorized fees or financial irregularities;
• the existence of multiple layers of regional or subordinate offices; and
• the risk that the relevant office may be dissolved, consolidated, or materially restructured.

Associations or affiliated bodies that do not comply with the Measures may warrant placement on an enhanced-review or restricted-engagement list.

3. Reassess Payment Arrangements

For conference sponsorships, exhibition fees, research collaborations, charitable contributions, and other association-related payments, companies should confirm that the payment process complies with the Measures’ centralized financial-management requirements. Complete records of contracts, approvals, payments, invoices, and project implementation should be retained.

Approval procedures should address, at a minimum:

• whether the payment recipient is the same entity as the contracting party;
• whether the funds will be deposited into an account centrally administered by the social organization;
• whether any secretariat, event organizer, third-party service provider, or other entity will collect or disburse funds on the association’s behalf;
• whether any third-party payment arrangement is properly authorized and supported by a legitimate business rationale; and
• whether the contracting party, payment recipient, and invoice issuer are appropriately aligned.

4. Monitor the Transition Period for Long-Term Projects

For ongoing or planned long-term academic collaborations, research projects, and framework agreements, companies should monitor changes to the relevant association’s organizational structure and authorization arrangements during the transition period. Where necessary, the parties may need to revise the contracting entity, payment arrangements, or other contractual provisions to reduce performance and enforcement risks arising from the restructuring of a branch office.

V. Conclusion

The Measures reflect the Chinese authorities’ continued efforts to strengthen the governance and financial transparency of social organizations. Although they do not directly regulate life sciences companies, they may materially affect how industry associations and their branch offices operate—and, in turn, how life sciences companies structure academic programs, continuing medical education, research collaborations, sponsorships, and other association-related projects.

Life sciences companies should assess their existing collaboration models and third-party risk management procedures in light of the Measures. They should also monitor the restructuring of industry associations during the 12-month transition period and the development of regulatory and enforcement practice following the Measures’ implementation.

^{This is a publication of Loeb & Loeb and is intended to provide information on recent legal developments. This publication does not create or continue an attorney client relationship nor should it be construed as legal advice or an opinion on specific situations.}